fbpx
 

Dear friends,

This was a landmark year at The Max Foundation. We reflected on our past, applied lessons learned over two decades, and turned the page to an exciting new chapter in the life of our organization – an innovative, humanitarian, access-to-treatment model we call Max Access Solutions.

Though we were celebrating our 20th anniversary, 2017 still brought us many firsts. From building out our supply chain capabilities and becoming a licensed wholesaler, to maintaining drug inventories and visiting more than 50 partner sites, we wrote a new script for ourselves at every turn. Driven by the unmet needs of people facing cancer around the world, we implemented an organizational transformation that will allow us to better serve the patients we support and, one day, scale our treatment access model across every type of cancer.

Continue Reading Pat's Letter

For much of our history, we’ve managed patient access programs in partnership with pharma companies. In fact, we first began our treatment access work by co- developing a drug delivery model with Novartis – the Glivec® International Patient Assistance Program (GIPAP) – back in 2001. GIPAP, and programs like it, allowed us a unique opportunity to help patients. Yet, throughout the GIPAP years, we dreamed that one day we would be able to provide access for our patients to any medicine they needed, beyond Glivec®.

Today, this dream has come true. In 2017, moving away from the drug-centric approach, we implemented a new model that would be truly patient-centric: Max Access Solutions. In our new model, we have a way to offer multiple therapies to the same patient as prescribed by their doctor – and a way for any company that is willing to help to join in our mission.

We now offer a portfolio of eight, innovative, high-quality medicines to cancer patients in low- and middle-income countries through a collaborative mechanism I call our Humanitarian Partnership for Access to Cancer Treatment (PACT); and for those patients living with chronic myeloid leukemia (CML), we are able to channel any treatment otherwise only available in high-income countries.

This Humanitarian PACT has already been a dream come true. Now we have a new dream. Our dream is a world where every manufacturer of cancer treatment is part of our PACT, and together we ensure that, to the extent that patients can safely be treated in countries with no other form of local access, we activate the Max Access Solution so no patient goes without medicine.

I am so proud of all we’ve accomplished in 2017 – and in our first 20 years as an organization. As you read our annual report, I hope you are too. We couldn’t have done it without you. Thank you for your continued support as we turn the page to our next 20 years.

In partnership,
Pat Garcia-Gonzalez,
CEO of The Max Foundation

Max Access Solutions

At The Max Foundation, we believe everyone deserves access to cancer treatment – no matter who they are or where they live. So, in 2017 we launched an innovative patient-centered model for delivering cancer treatment to those in need: Max Access Solutions.

Focused specifically on low- and middle-income countries, Max Access Solutions allows us to deliver targeted cancer treatments to patients who would have no other way to access them. Thanks to a proprietary, real-time, patient-tracking tool and our global system of collaborations, we’re able to deliver the right treatment to the right patient in the right dose at the right time.

In 2017, our first full year turning the page to Max Access Solutions, we successfully delivered 713,695 daily doses of cancer medication to 11,017 patients in 66 countries. In the years to come, we aim to complete the transition and move all the patients we currently support into this new model.

A Patient-Centered Model

A patient-centered model means we can offer multiple treatment options for the same disease. So when Alassane – a husband and father from Senegal – needed to change medications, he was able to get a second-line treatment through Max Access Solutions.

A New Path

In 2017, our longtime partnership with Novartis was reimagined as a best practice collaboration called CMLPath to Care™. Implemented under the umbrella of Max Access Solutions, the contribution of CMLPath to Care™ is enormous. Of the 700,000+ daily doses we distributed in our first year, 91% were Novartis’ transformative treatment, Glivec®.

MAX ACCESS SOLUTIONS

Network of Doctors

Doctors are the access point through which patients enter Max Access Solutions. When a doctor diagnoses a patient with cancer and prescribes a drug that’s not available locally, they set our access solution in motion.

From there, a complex system is activated: donated medicines leave the manufacturing plant, get routed through our validated supply chain, to our partner institutions, and into the patient’s hand. Though we only launched Max Access Solutions in January of 2017, by the end of the calendar year we had added more than 220 doctors around the globe to our network.

We’re proud to be affiliated with so many dedicated doctors and healthcare providers. They form the front line in bringing dignity and hope to people facing cancer. Without them, we could never achieve our mission. We look forward to adding more ways to support these key partners as our transition to Max Access Solutions continues.

The “Mother Teresa of Uzbekistan”

Meet Dr. Khamida Kazakbaeva. Lovingly known as the “Mother Teresa of Uzbekistan” among those she supports, she has dedicated her life to her patients.

She is the only trained hematologist in her region, so many of her patients must travel hundreds of miles to see her for checkups and refilling medications. To lessen the burden on them, Dr. Kazakbaeva created a biannual fundraiser called “Closer to Patients, Closer to Max.” She uses the money raised to fund her travel to four strategic areas around the country, setting up a mobile clinic in each where local patients can visit her nearby, rather than making the days-long journey to Tashkent.

We at The Max Foundation are humbled by Dr. Kazakbaeva’s dedication and honored to help her bring dignity and hope to people facing cancer in Uzbekistan.

“I had the honor of meeting Dr. Kazakbaeva in Uzbekistan and accompanied her on several home visits to treat patients and deliver their medicine. It was so humbling to see the strong relationships she has built with each one. Like all the physicians in our network, Dr. Kazakbaeva serves as an inspiration to do all we can for patients.”

Erin Lindsay Schneider, Senior Program Manager, USA

MAX ACCESS SOLUTIONS

Donated Medicine

Max Access Solutions is all about providing dependable access to quality treatments that would otherwise be unavailable. To that end, we’ve partnered with pharmaceutical companies who generously provide the prescribed medication for the patients we support.

Having multiple partners allows us to offer multiple targeted therapies – empowering doctors and patients to make choices about treatment. And, as our drug portfolio has grown, so have the disease areas in which we work.

When we first launched The Max Foundation 20 years ago, our focus was on rare blood cancers. Today, we also offer therapies for gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), and non-small cell lung cancer. Our next goal is to continue to expand the portfolio of medications available in every country in which we work.

In 2017, 66 countries gained access to cancer treatment through Max Access Solutions.
AR2017-9-map
A Pact for Access

Five multinational pharmaceutical companies have joined with us to forge a Humanitarian Partnership for Access to Cancer Treatment (PACT) – a commitment to providing cancer medicine to patients in low- and middle-income countries who would have no other means of access. Each company within the PACT has committed to providing access for a different number of patients within their capabilities, but all have committed their support for as long as each patient needs it.

NOVARTIS PFIZER TAKEDA INCYTE BRISTOL-MEYER SQUIBB
Glivec® Sutent® Iclusig™ Iclusig™ Sprycel™
Tasigna® Bosulif®
Torisel®
Xalkori®

MAX ACCESS SOLUTIONS

Shipping & Logistics

Our partnership with the dedicated team at Tanner Pharma Group allowed us to grow our shipping capacity rapidly in 2017. In January, we were only distributing medicine to a handful of countries, but by year’s end, that number had grown to 66.

With Tanner’s help – and in Max Access Solution’s inaugural year – we successfully delivered 147 shipments of targeted cancer medications to doctors and clinics the world over; monitoring their safety and quality from end-to-end along our validated supply chain.

And, we overcame some major barriers along the way: an earthquake, a volcanic eruption, and a political revolution; yet we endured and successfully delivered the needed medication to our patients.

“Without The Max Foundation’s effort in bringing the treatment access program to our hospital, patients in East Malaysia would have to travel to the capital of our country (only by air) to receive treatment for their cancer. This is an impossible journey for many to make on a regular basis, which would leave them with no access to treatment at all! Thanks to you, they have the care they need, but also, they have hope.”

Dr. Lu Chee Men, Queen Elizabeth II Hospital, Malaysia

Partner Hospitals and Clinics

In 2017, we established a validated supply chain into 98 cancer-treating institutions around the world.

See All 98 Cancer-Treating Institutions

Republican Haematology Centre · Armenia

Inst. of the Rep. of Azerbaijan on Tranfusiology and Hematology · Azerbaijan

Hematology Oncology Consultants · Bahamas

Belorussian Hematology and Bone Marrow Transplant · Belarus

Centre National Hospitalier Universitaire Hubert K. MAGA · Benin

Jigme Dorji Wangchuck National Referral Hospital · Bhutan

Clínica Los Olivos · Bolivia

Diagnosis Instituto de Medicina · Bolivia

Hospital de Clínicas Universitario · Bolivia

Hospital Universitario Santa Bárbara · Bolivia

Instituto Boliviano de Oncohematología · Bolivia

Instituto Oncologico del Oriente Boliviano · Bolivia

Centro de Hematologia e Hemoterapia – U. Estadual de Campinas · Brazil

Hospital das Clinicas das UFG · Brazil

Centre Hospitalier Universitaire Yalgado Ouedraogo · Burkina Faso

Mercy Medical Center · Cambodia

Hospital General Yaoundé · Cameroon

CHU de Yopougon · Cote d’Ivoire

Centre Hospitalier Monkole · Democratic Republic of Congo

Bairo Pite Clinic Lanud · East Timor

North Estonia Medical Center · Estonia

Tikur Anbessa (Black Lion) Hospital · Ethiopia

Colonial War Memorial Hospital · Fiji

Institut de Cancerologie Angondje · Gabon

Hematology and Chemotherapy Clinic “HEMA” · Georgia

Tbilisi Gov. Inst. of Hematology and Transfusion · Georgia

Komfo Anokye Teaching Hospital · Ghana

Korle-Bu Teaching Hospital · Ghana

Zanmi Lasante · Haiti

Centro de Cancer Emma R. De Callejas · Honduras

Apollo Speciality Hospital (Delhi) · India

Rajiv Gandhi Cancer Institute & Research Ctr. · India

Sir Ganga Ram Hospital · India

VPS Lakeshore Hospital · India

Cornwall Regional Hospital · Jamaica

Kingston Public Hospital · Jamaica

University Hospital Of The West Indies · Jamaica

Regional Hospital · Kazakhstan

Scientific Center of Pediatrics and Pediatrics Surgery · Kazakhstan

The Nairobi Hospital · Kenya

The National Centre of Oncology · Kyrgyzstan

Oncology and Transfusion Medicine Centre Vilnius University · Lithuania

Service d’Oncologie C.H.U – H.J.R.A · Madagascar

College of Medicine & Queen Elizabeth Central Hospital · Malawi

Hospital Ampang · Malaysia

Hospital Miri · Malaysia

Hospital Pulau Pinang · Malaysia

Hospital Queen Elizabeth · Malaysia

Hospital Raja Permaisuri Bainun · Malaysia

Hospital Sibu · Malaysia

Hospital Sultanah Aminah · Malaysia

Hospital Tengku Ampuan Afzan · Malaysia

Hospital Umum Sarawak · Malaysia

Subang Jaya Medical Centre · Malaysia

Service d’Hématologie Oncologie Médicale · Mali

Victoria Hospital Candos · Mauritius

Hosp. Central de San Luis Potosí “Dr. Morones Prieto” · Mexico

Hosp. Chiapas nos Une “Dr. Gómez Maza” · Mexico

Hospital General de Mexico · Mexico

Hospital General de Occidente, Secretaria de Salud · Mexico

Hosp. U. de Nuevo León “Dr. José Eleuterio González” · Mexico

Instituto Nacional de Cancerologia (INCAN) · Mexico

Inst. Nacional de Ciencias Médicas y Nutrición · Mexico

Unidad de Hematología y Transfusión · Mexico

Institute of Oncology · Moldova

First Central Hospital · Mongolia

B.P. Koirala Memorial Hospital · Nepal

Patan Hospital · Nepal

Hospital Roberto Calderon Gutierrez · Nicaragua

Hôpital National de Niamey · Niger

Obafemi Awolowo University Teaching Hospital · Nigeria

University of Nigeria Teaching Hospital · Nigeria

Nazarene Hospital · Papua New Guinea

Hospital de Clínicas · Paraguay

Philippine General Hospital · Philippines

Univ. of Santo Tomas Hospital · Philippines

Centre Hospitalier et Univ. de Brazzaville · Republic of Congo

Rwanda Military Hospital · Rwanda

Rwinkwavu District Hospital · Rwanda

Victoria Hospital · Saint Lucia

Hospital Dalal Jamm · Senegal

Seychelles Hospital · Seychelles

Connaught Teaching Hospital · Sierra Leone

National Referral Hospital · Solomon Islands

The Radiation and Isotope Centre · Sudan

University Hospital Paramaribo · Suriname

National Medical Center · Tajikistan

Kilimanjaro Christian Medical Center · Tanzania

Ocean Road Cancer Institute · Tanzania

Ramithibodi Hospital · Thailand

Siriraj Hospital · Thailand

Campus Teaching Hospital of Lome · Togo

Joint Clinical Research Center · Uganda

Mulago Hosp. Uganda Cancer Institute · Uganda

Inst. of Blood Pathology and Transfusion Med. · Ukraine

Scientific Research Inst. for Hem. and Blood Transfusion · Uzbekistan

University Teaching Hospital · Zambia

Parirenyatwa Hospital · Zimbabwe

MAX ACCESS SOLUTIONS

Wraparound Support

Wraparound support is key to the success of Max Access Solutions: we monitor each patient’s medication needs in our real-time tracking system, provide one-on-one care, connect them to local patient groups, and fund community education and diagnostic access.
Real-Time Tracking

The Max Foundation developed its own real-time program management tool – Patient Access Tracking System (PATS®) – that can be used simultaneously by our own program team and by treating physicians at partner institutions. Creating this sophisticated tool that can operate in low-resource settings has put The Max Foundation ahead of the curve in providing a complete, end-to-end access solution. PATS® is able to support the program on one end improving patients’ ability to comply with treatment, while on the other end supporting the implementation of successful planning and forecasting models.

Patient Support Program

For people living with cancer, finding a balance between daily cancer care and living without worry is vital. Our Day by Day support program is implemented through regular phone calls, distribution of informational materials and, in specific cases, patient support meetings and disease workshops hosted by our local representative in the patient’s country. Knowing that some kinds of cancer have become chronic conditions, attending to both the short- and long-term needs of patients and families is critical.

Increasing Diagnostic Access

One of the biggest barriers to cancer treatment access in low- and middle-income countries is the shortage of molecular diagnostic tools such as polymerase chain reaction (PCR) testing. In addition to its diagnostic function, PCR testing is also the best way to monitor a patient’s ongoing response to treatment, but many countries lack access to – or even awareness of – these critical tools. So we’ve started several initiatives to help close the gaps:

My PCR

In 2017, we developed an advocacy toolkit for leaders of patient associations and provided 27 grants to patient associations for PCR awareness activities – all through My PCR (mypcr.org).

A Preferential Pricing Agreement

Through a preferential pricing agreement with Cepheid, we channeled
250 test kits to hospitals and clinics, providing diagnostic access to 2,500 patients in 2017.

Spot On CML

Through a diagnostic partnership with the Fred Hutchinson Cancer Research Center, we made it possible for 61 patients to access free testing using dried blood samples on paper cards – a method pioneered by the Radich Lab.

“Twice a month I travel many hours by bus from Santo Domingo, to Santiago, accompany patients to get their blood samples, and bring the samples back to Santo Domingo so they can be PCR tested at Hospital Heriberto Pieter, where the GeneXpert machine is located.”

Nilexis Bernard Rodríguez
Program Coordinator, Dominican Republic

Financials

The planned transition of the GIPAP program to CMLPath to Care™ under the umbrella of the Max Access Solutions model, launched in July of 2017, required the organization to stock up its inventory to ensure a continuous supply of medicines to patients in the program.

While 50 out of the 67 countries to be transitioned did so in 2017, at year end, the organization was holding a substantial volume of inventory on hand while we sought import permits and other necessary regulatory documentation for distribution at the different sites.

Revenue
AMOUNT PERCENTAGE
Gifts-In-Kind · Pharmaceuticals 190,595,434 96.6%
Corporate Services Agreements 1,070,985 0.5%
Contributions, Grants & Sponsorships 5,386,877 2.7%
Diagnostic Program Revenue 312,689 0.2%
Other Income 9,127 0.0%
Total 197,375,112 100.0%
Expenses
AMOUNT PERCENTAGE
Program Services Expense 54,727,479 97.8%
Management & General 742,814 1.3%
Fundraising 482,926 0.9%
Total 55,953,219 100.0%
“At the 2017 Annual Board meeting, one of the Directors called our growth chart a ‘hockey stick’ in reference to its steep curve. I believe this is a very accurate representation of the truly transformative year, as we took on the role of drug delivery, which brings added responsibility in asset management. We look forward to increasing our impact on behalf of patients everywhere.”

Patricia Pearce, Chief Financial Officer Consultant

Valuation of Gifts-In-Kind

Prior to 2017, The Max Foundation’s fair value of donated pharmaceuticals was based on prices from Thomas Reuters Red Book Average Wholesale Price (AWP). During 2017, The Max Foundation obtained fair value data from a third-party source which reflects wholesale prices available in multiple relevant international markets. The gifts-in-kind are recorded, by drug, based on the estimated fair value in the relevant international market of highest volume. During 2017, The Max Foundation modified its agreements with several pharmaceutical companies. Pharmaceutical gifts-in-kind are now donated to The Max Foundation for use in its programs, whereas in prior years the pharmaceuticals were provided directly by the companies to the end users. As a result, the volume and total value of gifts-in-kind recognized in the consolidated financial statements is significantly higher in 2017.

To Our Partners

We offer our heartfelt thanks to our partners and friends for sharing in our mission.

Corporate Partners

AbbVie

Amgen

ARIAD

Bristol-Myers Squibb

Incyte

Janssen

Novartis

Otsuka

Pfizer

Takeda

Friends of The Max Foundation

Andrew W. Lyon Travel

Beresford Booth, PLLC

Bourne Capital Partners, LLC

Cepheid

Choice Organic Teas

Davis Wright Tremaine LLP

Expertasia Marketing Consulting & Services Co.

Fred Hutchinson Cancer Research Center

Global Fiberglass Solutions, Inc.

Greenwood Masonic Lodge

La Minutera Seafood Restaurant

Latin America Leukemia Net

Make Beautiful

Rainier Masonic Lodge

Tanner Pharma Group

The Woodshed Gallery

UNITS Moving & Portable Storage Seattle & Bellevue

Donors Make the Difference

Your support allows us to extend the reach of our programs and expand the services we offer to people facing cancer. Every dollar given, hat knitted, event hosted, and story shared brings a patient closer to accessing treatment – and access to treatment is access to life. To honor those who have been so generous and faithful in their support, here’s a look back at some of the ways our community supported patients in 2017.

“We meet patients at their lowest point, on the first step of facing cancer. When you help a patient get the treatment they need, this depression is turned around, filling them with hope and possibility. By supporting their care, you are turning their life around completely.

Priyanka Kandalgaokar, Program Officer, India

The Max Global Experience is a new fundraising and engagement event in which supporters travel together with us to gain a better under- standing of our work, meet patient leaders, and share in an unforgettable adventure. In 2017, 23 participants traveled to Malaysia to climb Mount Kinabalu with local cancer survivor and patient advocate, Tony Leo. Leading up to the event, participants tapped into their personal networks,introducing us to supporters who donated more than $105,000 toward education, awareness, and treatment access.

With Love in Every Stitch is a program inviting our community to donate hand-knit hats for children facing cancer. We received 374 handmade items in 2017 and sent them to patient organizations to give out in hospitals in Mexico, Chile, Mongolia, and Ethiopia – all thanks to the tireless work of our knitters.

Chai for Cancer USA, an initiative started by our South Asia Region Head, Viji Venkatesh, raises funds and awareness for people facing cancer in India. In 2017 we mailed chai tea to more than 400 participants so they could join in a virtual adda, raising a cup to benefit patients in India.

Our 20th Anniversary Celebration was held in Seattle, Washington, on Max’s Day – October 19th. Nearly 200 friends, partners, and guests from around the world joined us for a night of festivities and reflection. Staffed by community volunteers, the event brought in $100,000 in sponsorships and donations – and the first $20,000 was matched by a generous supporter.

“It is crushing to learn you have cancer. In the moment it is a huge truth to take in. Once you pass that moment, it’s what you do next that counts – this is a chance for us to be better and stronger than before, to inspire and bless others!”

Tony Leo, Patient Leader, Malaysia

To Our Donors

We are grateful to all the new friends we made in 2017, and the old friends who have been by our side for years. We thank you all for sharing in our daily mission and our nightly dream – creating a world in which all people face cancer with dignity and hope. Your ongoing support has a direct impact on patients and their families. By giving them access to cancer treatment, you are giving them the gift of time with loved ones.

Our Team

BOARD OF DIRECTORS

Paula Boultbee · President of the Board · Principal at PTB Consulting LLC

Jerry Scott, CPA · Treasurer of the Board · Chartered Global Management Accountant

David Tingstad · Secretary of the Board · Beresford Booth PLLC Law

Pat Garcia-Gonzalez · Chief Executive Officer & Founder

Robert Farmer · Board Member · CML Survivor & Photographer

Tracey Higgins · Board Member · Edmonds Community College

Grant Rubenstein · Board Member · Rosen~Harbottle Commercial Real Estate

MEDICAL ADVISORY BOARD

Hematology Advisors

Michele Baccarani, MD

Jorge E. Cortes, MD

Brian J. Druker, MD

Francois Guilhot, MD

Andreas Hochhaus, MD

Timothy Hughes, MD

Michael J. Mauro, MD

Javier Pinillia-Ibarz, MD

Delphine Rea, MD

Neil P. Shah, MD

Moshe Talpaz, MD

Oncology Advisors

Matía Chacón, MD

George D. Demetri, MD

Peter Reichardt, MD

Jonathan Trent, MD

Strategic Innovation Advisory Board

Carolyn Blasdel, FNP-BC

R. Banks Bourne, MBA

Rhonda Curry

Gilberto de Lima Lopes, Jr., MD

Michele Galen, J.D.

Teresa Guillien, MPA

William E. Heisel

Michael Mandola, PhD

Jerald Radich, MD

Carlos Rodriguez-Galindo, MD

Lawrence N. Shulman, MD

Andy Stergachis, PhD

Kristofer Rogers

LEADERSHIP TEAM

Pat Garcia-Gonzalez, Chief Executive Officer

Erin Schwartz, VP of Global Engagement

Inés García González, Region Head Latin America

Mei Ching Ong, Region Head Asia Pacific

Danielle Matia, Region Head Africa & Middle East

Viji Venkatesh, Region Head South Asia

Ann Kim Novakowski, Associate Program Director

J. Michael Wrigglesworth, Director of Global IT Solutions

GLOBAL HEADQUARTERS

Seattle, Washington, USA

Craig Anderson, Director of IT

Josué Blanco, Senior Brand Manager

Barbara Carpenter, Executive Assistant

Courtney Czarnecki, Administrative Assistant

Lorie Gail, Consulting Controller

Paula Lacy, Administrative Assistant

Scott Lutz, Accountant Assistant

Meg Mager, Senior Program Manager

Patricia Pearce, CFO Consultant

Kristina Pfeil, Human Resources Consultant

Winona Rennick, Development Manager

Erin Lindsay Schneider, Senior Program Manager

Scott Shearer, Quality Assurance Consultant

Huey Yeh, Controller

ARGENTINA

Mercedes Arteaga, Regional Program Officer

Maria Victoria Duhalde, Local Program Coordinator

Melisa Fazio, Local Program Coordinator

CHILE

Lyat Granati, Local Program Coordinator

DOMINICAN REPUBLIC

Martha Rosario Molina, Local Program Coordinator

Nilexis Bernard Rodríguez, Local Program Coordinator

ETHIOPIA

Tenaye A. Ashebir, Local Program Coordinator

GUATEMALA

Evelyn Berduo, Local Program Coordinator

INDIA

Ankita Borkar, Administrative Executive

Phillip Fernandes, Administrative Assistant

Santosh Kadam, Accounts/Office Manager

Priyanka Kandalgaokar, Program Officer

Prasad Kothekar, Administrative Executive

Sherly Kochi, Volunteer

Azim Mohd, Driver

Ashika Naik, Local Program Coordinator

Beena Narayanan, Program Officer

Jyotiy Parameshwaran, Local Program Coordinator

Sudha Samineni, Program Officer

Shalini Subramanian, Local Program Coordinator

Vijaya Sundaram, Program Officer

Ameya Surve, Program Officer

Komal Surve, Local Program Coordinator

Vidya Tahilramani, Local Program Coordinator

Anshika Tandon, Local Program Coordinator

Julie Soundarva, Housekeeping Staff

KENYA

Lucy Mwangi, Local Program Coordinator

MALAYSIA

Ghai Yein Lee, Local Program Coordinator

Nor Aina Binti Abd Rahim, Administrative Executive

Yee Jia Heng, Program Officer

Shirleen Low, Program Officer

MEXICO

Cynthia Figueroa Guerra, Program Officer

Mariana Rubi Gonzalez, Local Program Coordinator

NIGERIA

Adetokunbo M. Bello, Local Program Coordinator

NEPAL

Sweta Agrawal, Local Program Coordinator

PHILIPPINES

Nelia Media, Program Officer

SENEGAL

Mame Fall, Local Program Coordinator

SOUTH AFRICA

Geraldine Botha, Local Program Coordinator

Catherina Scheepers, Regional Program Officer

THAILAND

Krittapart Artharn, Local Program Coordinator

Thaned Kairaj, Local Program Coordinator

Wirat Sae-Kuai, Program Officer

Piyapong Siriviriyanum, Program Officer

UZBEKISTAN

Sukrob Saliev, Local Program Coordinator

VIETNAM

Tang Thi Thanh Thao, Local Program Coordinator

Patient Associations

What started as a small patient gathering in a hospital in Manila, has evolved into a global network of 77 independent patient associations in 57 countries whose efforts are central to our wraparound support.

Asociación de Leucemia Mieloide Argentina · Argentina

CML Patient Association Armenia · Armenia

Bangladesh CML Supporting Group · Bangladesh

Celebrando la Vida · Bolivia

Fundación Esperanza Nueva Bolivia

ABRALE · Brazil

Groupe d’Appui aux Survivants du Cancer · Burkina Faso

Max Miracle · Cambodia

AMACAS · Cameroon

Corporación Nacional Maxi Vida Chile · Chile

Shanghai Roots and Shoots · China

Fundación Colombiana de Leucemia y Linfoma · Colombia

Fundación Esperanza Viva · Colombia

Agalemo · Costa Rica

Un Paso Max · Dominican Republic

Esperanza y Vida · Ecuador

CanSurvive · Egypt

Asociación Amor a la Vida · El Salvador

Mathiwos Wondu-YeEthiopia Cancer Society · Ethiopia

CML Patients’ Foundation of Ethiopia · Ethiopia

The Alliance of CML Patients of Georgia · Georgia

Chronic Myeloid Leukemia Advocates of Ghana · Ghana

Asociación de Pacientes con Leucemia Mieloide Crónica · Guatemala

Asociación Hondureña de Lucha contra el Cáncer · Honduras

Friends of Max · India

ELGEKA West Java · Indonesia

YKI Jakarta · Indonesia

Israel CML Patients Organization · Israel

IZUMI · Japan

Association of Patients with Hemoblastoses · Kazakhstan

Childhood Cancer Initiative · Kenya

Henzo Kenya · Kenya

Nakuru Hospice · Kenya

Association Fanomezana LMC · Madagascar

Max Family Society Malaysia · Malaysia

Association Leucémie, espoir Mali · Mali

Alianza Anticáncer Infantil, A.B.P. · Mexico

Asociación Mexicana de Leucemia y GIST · Mexico

Grupo Unido de Leucemia A.C. · Mexico

Manitas la Pulsera de Leucemia · Mexico

Luz de Vida · Mexico

National Cancer Council Mongolia · Mongolia

Association des Malades Atteints de Leucémies · Morocco

Blood Cancer Society Nepal Nepal

Children Cancer Foundation Nepal · Nepal

Fundación Alas de Vida · Nicaragua

Association de Lutte Contre la Leucémie · Niger

MaxCare Nigeria · Nigeria

KIRAN · Pakistan

Patient’s Friends Society-Jerusalem · Palestine

Fundación Unidos contra el Cáncer · Paraguay

Esperantra · Peru

Luz de Esperanza · Peru

Touched By Max · Philippines

Polish Association for CML Patients Aid · Poland

Associação Portuguesa contra a Leucemia · Portugal

A.G.I.L du Sénégal · Senegal

CML Association of Serbia · Serbia

Crusaders Club Ministry · Sierra Leone

Children’s Cancer Foundation Singapore

Slovenian Lymphoma & Leukemia Patient Association Slovenia

Childhood Cancer Foundation South Africa · South Africa

CMLSA · South Africa

People Living with Cancer South Africa

Korea Blood Cancer Association · South Korea

Zero Club CML · South Korea

Taiwan Bone Marrow Transplantation AssociationTaiwan

Tanzania CML Patient Group Tanzania

MaxSmiles · Thailand

NGO APSBES/DILIGENCE GROUP · Togo

Emirates Association for Cancer Support · UAE

Leukemia & GIST Advocacy Fraternity of Uganda · Uganda

Osanna · Ukraine

Uzbekistan CML Patients League · Uzbekistan

Asociación de Ayuda a Pacientes Hemato-oncológicos Venezuela

Max’s Vie · Vietnam

CML Zimbabwe · Zimbabawe

20 Years of Dignity & Hope

Twenty years ago, The Max Foundation began with a simple goal – to connect people in need of cancer treatment with key resources they might never have known about.

Today, we go beyond linking people to existing resources and, instead, create new ones ourselves. We’ve co-developed the most successful oncological patient access program in history, forged a Humanitarian PACT with five multinational pharmaceutical companies, and just this year, launched a new patient-centered model that could redefine the approach to cancer treatment access in our field.

It feels like nothing short of a dream. And it all started with a brave young boy named Max.

Maximiliano “Max” Rivarola was from Argentina, but he and his family had to travel across the globe to get treatment for his leukemia. Though he was given the best possible care in the United States, the therapies available at the time were not enough to save him.

When Max’s family was faced with the end of his life, instead of giving up hope, they marked a new beginning. The family started The Max Foundation to ensure all people could access the very best care, no matter where they live.

Look what happens when we work together.
Look what happens when we hope.
“Dear 17-year-old Max, today I can say that you have changed the world more than I could have ever imagined…Your name has become a symbol of hope, and I couldn’t be more grateful. We will continue the work of The Max Foundation for the next 20 years and beyond, for as long and as strong as we possibly can.”
Pat Garcia-Conzalez in a letter to Max
We hope you see yourself in this report. We certainly see you. For the past 20 years you’ve been by our side through each new chapter and we thank you for it. Your support has made our dreams come true – one…after another… after another.
Now it is time for a new dream, a new chapter, and the next 20 years.

Together, let’s turn the page
to a world where all people face cancer with dignity & hope.

At The Max Foundation, we are building a strong foundation today so people can continue facing cancer with dignity and hope tomorrow.

Stay connected to the journey. Follow along on social media.

Bring dignity and hope to those facing cancer. Donate today.

Give Dignity and Hope